Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWC20155/DWC20156 and DWC20162 DDI Study
NCT02952755Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWC20155 and DWC20156 in gastritis and Peptic ulcer disease (PUD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the time versus plasma concentration curve. Started Nov 2016; status: completed.
02
Drugs
DWC20155DWC20156
03
Conditions
gastritisPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02952755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952755.